Clinical trials are the backbone of medical advancements, but they face a persistent challenge: participant adherence. Non-adherence can skew results, impact outcomes, and undermine the effectiveness of health solutions. Enter digital adherence tools, which are revolutionizing the landscape by
The production of protein-based drugs is a cornerstone of modern medicine, offering treatments for a range of conditions from cancer to autoimmune diseases. Central to this process are Chinese hamster ovary (CHO) cells, which are widely used in the biotechnology industry for their ability to
A phase 1 clinical trial has brought new hope for patients with B-cell lymphoma, a type of blood cancer, through an innovative cell-based immunotherapy. Researchers from Washington University School of Medicine in St. Louis, along with other collaborators, have explored the safety and potential
Gene therapy, a revolutionary approach to treating and preventing diseases by modifying faulty genes, relies heavily on accurate measurement techniques. Ensuring the safety and efficacy of these treatments necessitates precise quantification of adeno-associated virus (AAV) vectors, which deliver
Glioblastoma multiforme, an aggressive form of brain cancer, has long been a formidable challenge in the medical field. With patient survival rates stagnating around 15 to 18 months, the need for innovative treatment approaches is critical. NeOnc Technologies, under the leadership of Dr. Thomas
The UK’s National Health Service (NHS) is grappling with significant challenges, including a critical backlog in diagnostic services and a shortage of specialist staff. These issues are leading to prolonged patient waiting times and inefficiencies in healthcare delivery. The NHS’s Long Term Wor
Prostate cancer remains one of the most common cancers among men, and while hormone therapies have significantly improved patient outcomes, resistance to these treatments is a major challenge. The emergence of NXP800, a novel drug currently under clinical trials, offers a promising new approach to
Precision oncology is revolutionizing cancer treatment by tailoring medical care based on the genetic makeup of a patient's tumor. However, significant disparities exist in the effectiveness and availability of these treatments among patients of different ancestries. This article delves into
The J.P. Morgan (JPM) Healthcare Conference marks the beginning of a new year for the healthcare industry, typically setting the tone for upcoming trends and innovations. Held annually at the Westin St. Francis in San Francisco, this prestigious event attracts a diverse group of stakeholders,
NEC Corporation and Biomy, Inc. have announced a groundbreaking partnership aimed at revolutionizing digital pathology through the integration of artificial intelligence (AI) and deep learning (DL). This collaboration, formalized in a recent Memorandum of Understanding (MoU), seeks to enhance
